Department of Obstetrics and Gynaecology, University of Melbourne, Gynaecology Research Centre, Royal Women's Hospital, Level 7, 20 Flemington Road, Parkville, Victoria 3052, Australia.
Molecular Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia.
Hum Reprod. 2016 May;31(5):999-1013. doi: 10.1093/humrep/dew047. Epub 2016 Mar 22.
STUDY QUESTION: Do endometriosis risk-associated single nucleotide polymorphisms (SNPs) found at the 12q22 locus have effects on vezatin ( ITALIC! VEZT) expression? SUMMARY ANSWER: The original genome-wide association study (GWAS) SNP (rs10859871), and other newly identified association signals, demonstrate strong evidence for ITALIC! cis-expression quantitative trait loci (eQTL) effects on ITALIC! VEZT expression. WHAT IS KNOWN ALREADY: GWAS have identified several disease-risk loci (SNPs) associated with endometriosis. The SNP rs10859871 is located within the ITALIC! VEZT gene. ITALIC! VEZT expression is altered in the endometrium of endometriosis patients and is an excellent candidate for having a causal role in endometriosis. Most of the SNPs identified from GWAS are not located within the coding region of the genome. However, they are likely to have an effect on the regulation of gene expression. Genetic variants that affect levels of gene expression are called expression quantitative trait loci (eQTL). STUDY DESIGN, SIZE, DURATION: Samples for genotyping and ITALIC! VEZT variant screening were drawn from women recruited for genetic studies in Australia/New Zealand and women undergoing surgery in a tertiary care centre. Coding variants for ITALIC! VEZT were screened in blood from 100 unrelated individuals (endometriosis-dense families) from the QIMR Berghofer Medical Research Institute dataset. SNPs at the 12q22 locus were imputed and reanalysed for their association with endometriosis. Reanalysis of endometriosis risk-association was performed on a final combined Australian dataset of 2594 cases and 4496 controls. Gene expression was performed on 136 endometrial samples. eQTL analysis in whole blood was performed on 862 individuals from the Brisbane Systems Genetics Study. Endometrial tissue-specific eQTL analysis was performed on 122 samples (eutopic endometrium) collected following laparoscopic surgery. VEZT protein expression studies employed ITALIC! n = 56 (western blotting) and ITALIC! n = 42 (immunohistochemistry) endometrial samples. PARTICIPANTS/MATERIALS, SETTING, METHODS: The women recruited for this study provided blood and/or endometrial tissue samples in a hospital setting. Genomic DNA was screened for common and coding variants. SNPs of interest in the 12q22 region were genotyped using Agena MassARRAY technology or Taqman SNP genotyping assay. Gene expression profiles from RNA extracted from blood and endometrial tissue samples were generated using Illumina whole-genome expression chips (Human HT-12 v4.0). Whole protein extracted from endometrium was used for VEZT western blots, and paraffin sections of endometrium were employed for VEZT immunohistochemistry semi-quantitative analysis. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 11 coding variants of ITALIC! VEZT (including one novel variant) were identified from an endometriosis-dense cohort. Polymorphic coding and imputed SNPs were combined with previous GWAS data to reanalyse the endometriosis risk association of the 12q22 region. The disease association signal at 12q22 was due to coding variants in ITALIC! VEZT or ITALIC! FGD6 (FYVE, RhoGEF and PH domain-containing 6) and SNPs with the strongest signals were either intronic or intergenic. We found strong evidence for ITALIC! VEZT cis-eQTLs with the sentinel SNP (rs10859871) in blood and endometrium, where the endometriosis risk allele (C) was associated with an increase in ITALIC! VEZT expression. We could not demonstrate this genotype-specific effect on VEZT protein expression in endometrium. However, we did observe a menstrual cycle stage specific increase in VEZT protein expression in endometrial glands, specific to the secretory phase ( ITALIC! P = 2.0 × 10(-4)). LIMITATIONS, REASONS FOR CAUTION: In comparison to the blood sample datasets, the study numbers of endometrial tissues were substantially reduced. Protein studies failed to complement RNA results, also likely a reflection of the low study numbers in these experiments. ITALIC! In silico prediction tools used in this investigation are typically based on cell lines different to our tissues of interest, thus any functional annotations drawn from these approaches should be considered carefully. Therefore, functional studies on VEZT and related pathway components are still warranted to unequivocally implicate a causal role for VEZT in endometriosis pathophysiology. WIDER IMPLICATIONS OF THE FINDINGS: GWAS have proven to be very valuable tools for deciphering complex diseases. Endometriosis is a text-book example of a complex disease, involving genetic, lifestyle and environmental influences. Our focused investigation of the 12q22 region validates an association with increased endometriosis risk. Endometriosis risk SNPs (including rs10859871) located within this locus demonstrated evidence for ITALIC! cis-eQTLs on ITALIC! VEZT expression. By examining women who possess an enhanced genetic risk of developing endometriosis, we have identified an effect on ITALIC! VEZT expression and therefore a potential gene/gene pathway in endometriosis disease establishment and development. STUDY FUNDING/COMPETING INTERESTS: Funding for this work was provided by NHMRC Project Grants GNT1012245, GNT1026033, GNT1049472 and GNT1046880. G.W.M. is supported by the NHMRC Fellowship scheme (GNT1078399). S.J.H.-C. is supported by the J.N. Peters Bequest Fellowship. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
研究问题:位于 12q22 位的子宫内膜异位症风险相关单核苷酸多态性(SNP)是否对 vezatin(ITALIC!VEZT)表达有影响?
总结答案:最初的全基因组关联研究(GWAS)SNP(rs10859871)和其他新发现的关联信号强烈表明,ITALIC!VEZT 表达的顺式表达数量性状基因座(eQTL)效应与 ITALIC!基因座的 cis 有关。
已知情况:GWAS 已经确定了几个与子宫内膜异位症相关的疾病风险位点(SNP)。SNP rs10859871 位于 ITALIC!VEZT 基因内。子宫内膜异位症患者的子宫内膜中 ITALIC!VEZT 的表达发生改变,并且是子宫内膜异位症发病机制中具有因果关系的绝佳候选者。从 GWAS 中鉴定的大多数 SNP 不位于基因组的编码区。然而,它们可能对基因表达的调节有影响。影响基因表达水平的遗传变异被称为表达数量性状基因座(eQTL)。
研究设计、规模、持续时间:来自澳大利亚/新西兰遗传研究和三级保健中心手术的女性的样本被用于基因分型和 ITALIC!VEZT 变体筛选。来自 QIMR Berghofer 医学研究所数据集的 100 个无关个体(子宫内膜异位症密集家族)的血液中筛选编码变体。对 12q22 位的 SNP 进行了推断,并对其与子宫内膜异位症的关联进行了重新分析。对澳大利亚的最终综合数据集 2594 例病例和 4496 例对照进行了子宫内膜异位症风险关联的重新分析。对 136 个子宫内膜样本进行了基因表达分析。在来自布里斯班系统遗传学研究的 862 名个体中进行了全血 eQTL 分析。对 122 个(腹腔镜手术后)收集的异位子宫内膜样本进行了子宫内膜组织特异性 eQTL 分析。VEZT 蛋白表达研究采用 ITALIC!n = 56(western blotting)和 ITALIC!n = 42(immunohistochemistry)子宫内膜样本。
参与者/材料、设置、方法:这项研究招募的女性在医院环境中提供了血液和/或子宫内膜组织样本。对基因组 DNA 进行常见和编码变体的筛查。使用 Agena MassARRAY 技术或 Taqman SNP 基因分型检测对 12q22 区域的感兴趣 SNP 进行基因分型。使用 Illumina 全基因组表达芯片(人类 HT-12 v4.0)生成来自血液和子宫内膜组织样本的 RNA 表达谱。从子宫内膜中提取的全蛋白用于 VEZT western blot,子宫内膜的石蜡切片用于 VEZT 免疫组织化学半定量分析。
主要结果和机会的作用:从子宫内膜异位症密集队列中鉴定出 11 种 ITALIC!VEZT 的编码变体(包括一种新变体)。将多态性编码和推断 SNP 与先前的 GWAS 数据相结合,重新分析了 12q22 区域的子宫内膜异位症风险关联。12q22 处的疾病关联信号归因于 ITALIC!VEZT 或 ITALIC!FGD6(FYVE、RhoGEF 和 PH 结构域蛋白 6)的编码变体,并且信号最强的 SNP 是内含子或基因间的。我们发现,在血液和子宫内膜中,信号 SNP(rs10859871)与 ITALIC!VEZT 的 cis-eQTL 有很强的证据,其中子宫内膜异位症风险等位基因(C)与 ITALIC!VEZT 表达增加有关。我们不能证明这一基因型在子宫内膜中对 VEZT 蛋白表达的特异性影响。然而,我们确实观察到 VEZT 蛋白表达在子宫内膜腺中存在与月经周期阶段特异性增加,具体而言是在分泌期(ITALIC!P = 2.0×10(-4))。
局限性、谨慎的原因:与血液样本数据集相比,子宫内膜组织的研究数量大大减少。蛋白质研究未能补充 RNA 结果,这也可能反映了这些实验中的研究数量较少。在这项研究中使用的 ITALIC!计算机预测工具通常基于与我们感兴趣的组织不同的细胞系,因此从这些方法中得出的任何功能注释都应谨慎考虑。因此,仍然需要对 VEZT 和相关途径成分进行功能研究,以明确确定 VEZT 在子宫内膜异位症发病机制中的因果作用。
研究结果的更广泛意义:GWAS 已被证明是解析复杂疾病的非常有价值的工具。子宫内膜异位症是一种复杂疾病的典型例子,涉及遗传、生活方式和环境影响。我们对 12q22 区域的重点研究验证了与增加子宫内膜异位症风险的关联。位于该基因座的子宫内膜异位症风险 SNP(包括 rs10859871)显示出对 ITALIC!VEZT 表达的 cis-eQTL 证据。通过检查具有增强的子宫内膜异位症发病风险的女性,我们已经确定了对 ITALIC!VEZT 表达的影响,因此在子宫内膜异位症疾病的建立和发展中可能存在一个潜在的基因/基因途径。
研究资金/利益冲突:这项工作的资金由 NHMRC 项目拨款 GNT1012245、GNT1026033、GNT1049472 和 GNT1046880 提供。G.W.M. 得到 NHMRC 研究员计划(GNT1078399)的支持。S.J.H.-C. 得到 J.N. 彼得斯奖学金的支持。作者没有利益冲突。
试验注册:无。
Hum Reprod. 2016-3-22
Hum Reprod. 2015-3-18
Hum Reprod. 2017-4-1
Cell Rep. 2024-11-26
Front Med (Lausanne). 2024-9-6
Comput Struct Biotechnol J. 2023-2-5
Front Reprod Health. 2022-1-3
Reprod Fertil. 2022-4-1
BMC Womens Health. 2021-9-20
Int J Mol Sci. 2021-7-7